Eph-A2 and Eph-A4 expression in human benign and malignant thyroid lesions: An immunohistochemical study

Medical Science Monitor

Volumn 17, Issue 9, 2011, Pages

  Karidis, Nikolaos P ^a   Giaginis, Constantinos ^a   Tsouroufis, Gerasimos ^a   Alexandrou, Paraskevi ^a   Delladetsima, Ioanna ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Clinicopathological parameters; Eph A2; Eph A4; Ephrin receptors; Immunohistochemistry; Thyroid malignancy

Indexed keywords

EPHRIN RECEPTOR A2; EPHRIN RECEPTOR A4;

ADULT; ANAPLASTIC CARCINOMA; ARTICLE; CANCER INVASION; CANCER STAGING; CONTROLLED STUDY; FEMALE; HASHIMOTO DISEASE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; PROTEIN EXPRESSION; THYROID DISEASE; THYROID FOLLICULAR CARCINOMA; THYROID GLAND; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROID TUMOR;

EID: 80054020590     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881929     Document Type: Article

References (54)

1. Gale NW, Yancopoulos GD: Ephrins and their receptors: a repulsive topic? Cell Tissue Res, 1997; 290(2): 227-41
2. Pasquale EB: Eph receptor signalling casts a wide net on cell behaviour. Nat Rev Mol Cell Biol, 2005; 6(6): 462-75
3. Kullander K, Klein R: Mechanisms and functions of Eph and ephrin signalling. Nat Rev Mol Cell Biol, 2002; 3(7): 475-86
4. Vearing CJ, Lackmann M: Eph receptor signalling; dimerisation just isn't enough. Growth Factors, 2005; 23(1): 67-76
5. Himanen JP, Saha N, Nikolov DB: Cell-cell signaling via Eph receptors and ephrins. Curr Opin Cell Biol, 2007; 19(5): 534-42
6. Wang HU, Chen ZF, Anderson DJ: Molecular distinction and angiogen-ic interaction between embryonic arteries and veins revealed by eph-rin-B2 and its receptor Eph-B4. Cell, 1998; 93(5): 741-53
7. Palmer A, Zimmer M, Erdmann KS et al: EphrinB phosphorylation and reverse signaling: regulation by Src kinases and PTP-BL phosphatase. Mol Cell, 2002; 9(4): 725-37
8. Carles-Kinch K, Kilpatrick KE, Stewart JC et al: Antibody targeting of the EphA2 tyrosine kinase inhibits malignant cell behavior. Cancer Res, 2002; 62(10): 2840-47
9. Miao H, Burnett E, Kinch M et al: Activation of EphA2 kinase suppresses integrin function and causes focal-adhesion-kinase dephosphoryla-tion. Nat Cell Biol, 2002; 2(2): 62-69
10. Hafner C, Schmitz G, Meyer S et al: Differential gene expression of Eph receptors and ephrins in benign human tissues and cancers. Clin Chem, 2004; 50(3): 490-99
11. Dodelet VC, Pasquale EB: Eph receptors and ephrin ligands: embryo-genesis to tumorigenesis. Oncogene, 2000; 19(49): 5614-19
12. Zelinski DP, Zantek ND, Stewart JC et al: EphA2 overexpression causes tumorigenesis of mammary epithelial cells. Cancer Res, 2001; 61(5): 2301-6
13. Brannan JM, Sen B, Saigal B et al: EphA2 in the early pathogenesis and progression of non-small cell lung cancer. Cancer Prev Res (Phila Pa), 2009; 2(12): 1039-49
14. Feng YX, Zhao JS, Li JJ et al: Liver cancer: EphrinA2 promotes tumorige-nicity through Rac1/Akt/NF-kappaB signaling pathway 120. Hepatology, 2010; 51(2): 535-44
15. Lu C, Shahzad MM, Wang H et al: EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther, 2008; 7(7): 1098-103
16. Nakamura R, Kataoka H, Sato N et al: EPHA2/EFNA1 expression in human gastric cancer. Cancer Sci, 2005; 96(1): 42-47
17. Walker-Daniels J, Coffman K, Azimi M et al: Overexpression of the EphA2 tyrosine kinase in prostate cancer. Prostate, 1999; 41(4): 275-80
18. Wykosky J, Debinski W: The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res, 2008; 6(12): 1795-806
19. Kinch MS, Moore MB, Harpole DH: Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. Clin Cancer Res, 2003; 9(2): 613-18
20. Meade-Tollin L, Martinez JD: Loss of p53 and overexpression of EphA2 predict poor prognosis for ovarian cancer patients. Cancer Biol Ther, 2007; 6(2): 288-89
21. Thaker PH, Deavers M, Celestino J et al: EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res, 2004; 10(15): 5145-50
22. Yuan W, Chen Z, Wu S et al: Expression of EphA2 and E-cadherin in gastric cancer: correlated with tumor progression and lymphogenous metastasis. Pathol Oncol Res, 2009; 15(3): 473-78
23. Garg M, Kanojia D, Suri S et al: Sperm-associated antigen 9: a novel diagnostic marker for thyroid cancer. J Clin Endocrinol Metab, 2009; 94(11): 4613-18
24. Solini A, Cuccato S, Ferrari D et al: Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology, 2008; 149(1): 389-96
25. Wiseman SM, Melck A, Masoudi H et al: Molecular phenotyping of thyroid tumors identifes a marker panel for differentiated thyroid cancer diagnosis. Ann Surg Oncol, 2008; 15(10): 2811-26
26. Kebebew E, Weng J, Bauer J et al: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg, 2007; 246(3): 466-70; discussion 470-71
27. Siironen P, Louhimo J, Nordling S et al: Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients. Tumour Biol, 2005; 26(2): 57-64
28. Wreesmann VB, Sieczka EM, Socci ND et al: Genome-wide profling of papillary thyroid cancer identifes MUC1 as an independent prognostic marker. Cancer Res, 2004; 64(11): 3780-89
29. Krawczyk-Rusiecka K, Lewinski A: Cycloogygenase-2 expression and its association with thyroid lesions. Arch Med Sci, 2010; 6(5): 653-57
30. th ed). New York, NY, Springer, 2010
31. Giaginis C, Tsouroufis G, Zizi-Serbetzoglou A et al: Clinical Signifcance of Ephrin (Eph)-A1, -A2, -A4, -A5 and -A7 Receptors in Pancreatic Ductal Adenocarcinoma. Pathol Oncol Res, 2010; 16(2): 267-76
32. Giaginis C, Davides D, Zarros A et al: Clinical signifcance of tumor-associated antigen RCAS1 expression in human pancreatic ductal ade-nocarcinoma. Dig Dis Sci, 2008; 53(6): 1728-34
33. Giaginis CT, Vgenopoulou S, Tsouroufis GS et al: Expression and clinical signifcance of focal adhesion kinase in the two distinct histological types, intestinal and diffuse, of human gastric adenocarcinoma. Pathol Oncol Res, 2009; 15(2): 173-81
34. Cho Mar K, Eimoto T, Tateyama H et al: Expression of matrix me-talloproteinases in benign and malignant follicular thyroid lesions. Histopathology, 2006; 48(3): 286-94
35. Melck A, Masoudi H, Griffth OL et al: Cell cycle regulators show diagnostic and prognostic utility for differentiated thyroid cancer. Ann Surg Oncol, 2007; 14(12): 3403-11
36. Wiseman SM, Griffth OL, Melck A et al: Evaluation of type 1 growth factor receptor family expression in benign and malignant thyroid lesions. Am J Surg, 195(5): 667-73; discussion 673
37. Giaginis C, Zarros A, Alexandrou P et al: Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. APMIS, 2010; 118(3): 210-21
38. Surawska H, Ma PC, Salgia R: The role of ephrins and Eph receptors in cancer. Cytokine Growth Factor Rev, 2004; 15(6): 419-33
39. Nakamoto M, Bergemann AD: Diverse roles for the Eph family of receptor tyrosine kinases in carcinogenesis. Microsc Res Tech, 2002; 59(1): 58-67
40. Ogawa K, Pasqualini R, Lindberg RA et al: The ephrin-A1 ligand and its receptor, EphA2, are expressed during tumor neovascularization. Oncogene, 2000; 19(52): 6043-52
41. Walker-Daniels J, Hess AR, Hendrix MJ et al: Differential regulation of EphA2 in normal and malignant cells. Am J Pathol, 2003; 162(4): 1037-42
42. Brantley-Sieders DM, Caughron J, Hicks D et al: EphA2 receptor tyro-sine kinase regulates endothelial cell migration and vascular assembly through phosphoinositide 3-kinase-mediated Rac1 GTPase activation. J Cell Sci, 2004; 117(Pt 10): 2037-49
43. Fang WB, Brantley-Sieders DM, Parker MA et al: A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene, 2005; 24(53): 7859-68
44. Huynh-Do U, Stein E, Lane AA et al: Surface densities of ephrin-B1 determine EphB1-coupled activation of cell attachment through alphav-beta3 and alpha5beta1 integrins. EMBO J, 1999; 18(8): 2165-73
45. Mudali SV, Fu B, Lakkur SS et al: Patterns of EphA2 protein expression in primary and metastatic pancreatic carcinoma and correlation with genetic status. Clin Exp Metastasis, 2006; 23(7-8): 357-65
46. Hess AR, Seftor EA, Gardner LM et al: Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Cancer Res, 2001; 61(8): 3250-55
47. Duxbury MS, Ito H, Zinner MJ et al: Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun, 320(4): 1096-102
48. Ruoslahti E: Fibronectin and its integrin receptors in cancer. Adv Cancer Res, 1999; 76: 1-20
49. Kataoka H, Igarashi H, Kanamori M et al: Correlation of EPHA2 over-expression with high microvessel count in human primary colorectal cancer. Cancer Sci, 2004; 95(2): 136-41
50. Vaiman M, Olevson Y, Habler L et al: Diagnostic value of estrogen receptors in thyroid lesions. Med Sci Monit, 2010; 16(7): BR203-7
51. Cho MA, Lee MK, Nam KH et al: Expression and role of estrogen receptor alpha and beta in medullary thyroid carcinoma: different roles in cancer growth and apoptosis. J Endocrinol, 2007; 195(2): 255-63
52. Gokmen-Polar Y, Toroni RA, Hocevar BA et al: Dual targeting of EphA2 and ER restores tamoxifen sensitivity in ER/EphA2-positive breast cancer. Breast Cancer Res Treat DOI: 10.1007/s10549-010-1004-y
53. Kamat AA, Coffey D, Merritt WM et al: EphA2 overexpression is associated with lack of hormone receptor expression and poor outcome in endometrial cancer. Cancer, 2009; 115(12): 2684-92
54. Kawabata W, Suzuki T, Moriya T et al: Estrogen receptors (alpha and beta) and 17beta-hydroxysteroid dehydrogenase type 1 and 2 in thyroid disorders: possible in situ estrogen synthesis and actions. Mod Pathol, 2003; 16(5): 437-44